Search

Your search keyword '"Akram Esfandani"' showing total 3 results
Start Over Author "Akram Esfandani" Publication Year Range Last 3 years
3 results on '"Akram Esfandani"'

1. A randomized open-label clinical trial on the effect of Amantadine on post Covid 19 fatigue

Author

Ali Amini Harandi, Hossein Pakdaman, Aida Medghalchi, Negin Kimia, Alireza Kazemian, Fatemeh Siavoshi, Siavash Shirzadeh Barough, Akram Esfandani, Mohammad Hossein Hosseini, and Seyed Ali Sobhanian

Subjects
Medicine, Science
Abstract

Abstract Many COVID-19 survivors experience lingering post-COVID-19 symptoms, notably chronic fatigue persisting for months after the acute phase. Despite its prevalence, limited research has explored effective treatments for post-COVID-19 fatigue. This randomized controlled clinical trial assessed the impact of Amantadine on patients with post-COVID-19 fatigue. The intervention group received Amantadine for two weeks, while the control group received no treatment. Fatigue levels were assessed using the Visual Analog Fatigue Scale (VAFS) and Fatigue Severity Scale (FSS) questionnaires before and after the trial. At the study's onset, VAFS mean scores were 7.90 ± 0.60 in the intervention group and 7.34 ± 0.58 in the control group (P-value = 0.087). After two weeks, intervention group scores dropped to 3.37 ± 0.44, significantly lower than the control group's 5.97 ± 0.29 (P-value

Published
2024
Full Text
View/download PDF

2. A long-term study of NeuroAid (MLC601, MLC901) in Patients with Alzheimer's disease; An Extension 8-year Follow-up Study

Author

Ali Amini Harandi, Hossein Pakdaman, Koroush Gharagozli, Fatemeh Siavoshi, Siavash Shirzadeh Barough, Ehsan Sharifipour, Akram Esfandani, Saba Ilkhani, Fatemeh Sadat Tabatabaei, and Seyed Ali Sobhanian

Subjects
Pulmonary and Respiratory Medicine, Pediatrics, Perinatology and Child Health
Abstract

Background: MLC601 and MLC901 showed neuroprotective and neuroregenerative properties and positive results in the treatment of dementia and cognitive impairment. This study aimed to investigate the long-term benefits of monotherapy with MLC601 and MLC901 in patients with Alzheimer's disease (AD). Methods: In this study, patients with AD, diagnosed by DSM-IV criteria, were enrolled. Patients have received MLC601 for four years, and their regimen has changed to MLC901 for another four years. Recruited patients were followed to assess the efficacy and safety first of MLC601 and MLC901. Mini-Mental State Examination (MMSE) and Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) were used to assess cognitive function. Safety was evaluated by monitoring adverse events (AEs) and abnormal findings in physical examinations or lab tests. Results: At the end of the trial, the changes in the mean (±SD) MMSE and ADAS-cog scores were 5.1 (3.09) and 12.5 (10.89), respectively. Both scores showed a significant change in repeated measure analysis, with the ADAS-cog score indicating a higher change than the MMSE score (P Conclusion: For more than eight years, we studied monotherapy with NeuroAid (MLC601, MLC901) in patients with AD. The study contributes further to the long-term safety and efficacy data of MLC in patients with AD. Trial Registration

Published
2023
Full Text
View/download PDF

3. Cerebral hemodynamic response to generalized anxiety disorder

Author

Ali Amini Harandi, Negin Kimia, Aida Medghalchi, Ehsan Sharifipour, Hossein Pakdaman, Fatemeh Siavoshi, Siavash Shirzadeh Barough, Akram Esfandani, and Mohammad hossein Hosseini

Subjects
Psychiatry and Mental health, Neuroscience (miscellaneous), Radiology, Nuclear Medicine and imaging
Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results